Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways.
説明 | RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways. |
ターゲット&IC50 | EGFR: |
In vitro | H1650 lung adenocarcinoma cell growth inhibited by RTC-5 (0-40 μM; 48 hours) (GI50 of 12.6μM). RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression[1]. |
別名 | TRC-382 |
分子量 | 510.96 |
分子式 | C24H22ClF3N2O3S |
CAS No. | 1423077-49-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 13.5 mg/mL (26.4 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RTC-5 1423077-49-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR RTC 5 TRC-382 TRC 382 TRC382 RTC5 Inhibitor inhibitor inhibit